Pharmaron Beijing revenue and financials
¥44.97Change from previous close: +4.63%Absolute change: +¥1.99
In the fiscal year ended December 2025, Pharmaron Beijing reported revenue of ¥14.1B (+14.82% year over year). Net income was ¥1.66B, a net margin of 11.8%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +14.82%
- 2025 vs 2024
- Net income growth
- −7.22%
- 2025 vs 2024
- Net margin
- 11.8%
- 2024: 14.6%
Financial data
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total assets | 28,946 | 28,562 | 27,094 | 25,197 | 24,333 |
| Current assets | 8,870 | 9,051 | 7,778 | 7,593 | 7,384 |
| Cash and equivalents | 1,576 | 2,379 | 1,017 | 1,302 | 1,263 |
| Short-term investments | 876 | 598 | 714 | 860 | 1,415 |
| Inventory | 1,935 | 1,694 | 1,472 | 1,305 | 1,167 |
| Net property, plant and equipment | 12,363 | 12,017 | 11,797 | 11,167 | 10,790 |
| Goodwill | 3,508 | 3,535 | 3,586 | 2,985 | 2,947 |
| Other intangible assets | 1,276 | 1,168 | 1,197 | 873 | 838 |
| Long-term investments | 791 | 646 | 640 | 713 | 727 |
| Current liabilities | 8,722 | 8,370 | 8,364 | 4,978 | 4,224 |
| Accounts payable | 761 | 628 | 607 | 528 | 484 |
| Long-term debt | 1,920 | 1,844 | 1,772 | 4,209 | 4,357 |
| Total debt | 6,954 | 7,101 | 7,040 | 6,081 | 5,959 |
| Total liabilities | 11,896 | 11,447 | 11,355 | 10,328 | 9,687 |
| Total equity (incl. minority) | 17,051 | 17,115 | 15,739 | 14,869 | 14,646 |
| Retained earnings | 8,064 | 8,014 | 7,679 | 6,791 | 6,748 |
| Minority interest | 702 | 656 | 674 | 603 | 604 |